Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

dosing

- PMLiVE

AstraZeneca’s Tagrisso shows promise as lung cancer maintenance therapy

Up to 85% of lung cancer patients are diagnosed with non-small cell lung cancer

HCP icons in Cuttsy+Cuttsy branded shapes

Clinical trial considerations: Why supporting HCPs matters…

When HCPs have the necessary information, they can more easily communicate it to patients using simplified language and a confident, calm tone.

Cuttsy + Cuttsy

- PMLiVE

AstraZeneca’s Tagrisso combination approved by FDA for advanced lung cancer

An estimated 200,000 people in the US are diagnosed with lung cancer every year

Diversity icons in Cuttsy+Cuttsy branded shapes

Clinical trial considerations: Why diversity matters…

Diversity in clinical trials is crucial for understanding diseases and developing new treatments. Here's why diversity matters...

Cuttsy + Cuttsy

Digital icon inside Cuttsy+Cuttsy branded shapes

Clinical trial considerations: Why digital matters…

Digital technology in healthcare is rapidly evolving. In this blog we delve into how digital solutions can help improve patient experience within clinical trials.

Cuttsy + Cuttsy

- PMLiVE

AstraZeneca shares positive phase 3 results for acoramidis in ATTR cardiomyopathy

Up to 500,000 people worldwide are affected by the rare and progressive condition

Imagery icons in Cuttsy+Cuttsy branded shapes

Clinical trials explained: Why imagery matters…

Recruiting patients for clinical trials is one of pharma's greatest challenges. Imagery is a great way to connect with people on an emotional level and forms a big part the...

Cuttsy + Cuttsy

Health literacy icons in Cuttsy+Cuttsy branded shapes

Clinical trials explained: Why health literacy matters…

Clinical trial recruitment can be a challenge. By applying the principles of health literacy to all materials, we can support people to make an informed choice about whether to take...

Cuttsy + Cuttsy

- PMLiVE

New framework establishes two tests for use in clinical trials for Parkinson’s

The neurological condition currently affects around 145,000 people in the UK

- PMLiVE

AstraZeneca’s Imfinzi combination shows promise in phase 3 liver cancer study

Hepatocellular carcinoma accounts for about 75% of all primary liver cancers in adults

icons related to iconography inside Cuttsy+Cuttsy branded shapes

Clinical trials explained: Why iconography matters…

Icons serve as a useful form of alternative communication. We spend a lot of time developing icons for healthcare communications. Find out how we use iconography to elevate clinical trial...

Cuttsy + Cuttsy

- PMLiVE

GSK to expand respiratory pipeline with $1.4bn Aiolos Bio acquisition

The deal includes a monoclonal antibody ready to enter phase 2 development for asthma

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links